Physician profile
Mark D Mayeda
NPI 1295181493
$2,354.54
in general payments reported to CMS, 2019-2025
22 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.99 · 2023: $307 · 2024: $959 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,340.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $630.00 | 2023-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $315.06 | 2024-2025 | |
| Fujifilm Healthcare Americas Corporation | $204.55 | 2024 | Utaswako Afp-L3 |
| Regeneron Healthcare Solutions, INC. | $154.54 | 2024-2025 | Libtayo |
| Coherus Oncology, INC. | $124.78 | 2024-2025 | Loqtorzi, Udenyca |
| Janssen Biotech, INC. | $113.30 | 2023-2025 | Erleada |
| Pfizer INC. | $100.13 | 2023-2024 | |
| Eisai INC. | $94.59 | 2024 | |
| Astellas Pharma US INC | $92.61 | 2023-2025 | Xtandi, Padcev, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $75.97 | 2023-2025 | Opdivo |
| Sumitomo Pharma America, INC. | $59.50 | 2024-2025 | Orgovyx |
| Merck Sharp & Dohme LLC | $54.91 | 2024-2025 | Keytruda, Keytruda Qlex |
| Teleflex LLC | $51.49 | 2025 | Barrigel |
| Incyte Corporation | $50.20 | 2024-2025 | Monjuvi, Zynyz, Pemazyre |
| Novocure INC. | $43.02 | 2024-2025 | Optune Gio, Optune |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $39.81 | 2024-2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $35.68 | 2025 | |
| Agios Pharmaceuticals, INC. | $30.78 | 2024 | Pyrukynd |
| Exelixis INC. | $26.15 | 2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $25.64 | 2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.84 | 2025 | |
| Monteris Medical Corporation | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mayeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.